Would Extrawell Pharmaceutical Holdings (HKG:858) Be Better Off With Less Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that Extrawell Pharmaceutical Holdings Limited (HKG:858) does use debt in its business. But the more important question is: how much risk is that debt creating?

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Why Does Debt Bring Risk?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. When we think about a company's use of debt, we first look at cash and debt together.

What Is Extrawell Pharmaceutical Holdings's Net Debt?

You can click the graphic below for the historical numbers, but it shows that as of September 2025 Extrawell Pharmaceutical Holdings had HK$151.5m of debt, an increase on HK$127.6m, over one year. On the flip side, it has HK$94.4m in cash leading to net debt of about HK$57.1m.

How Strong Is Extrawell Pharmaceutical Holdings' Balance Sheet?

According to the last reported balance sheet, Extrawell Pharmaceutical Holdings had liabilities of HK$49.1m due within 12 months, and liabilities of HK$155.6m due beyond 12 months. Offsetting these obligations, it had cash of HK$94.4m as well as receivables valued at HK$521.5m due within 12 months. So it can boast HK$411.2m more liquid assets than total liabilities.

This excess liquidity is a great indication that Extrawell Pharmaceutical Holdings' balance sheet is almost as strong as Fort Knox. On this view, lenders should feel as safe as the beloved of a black-belt karate master. There's no doubt that we learn most about debt from the balance sheet. But it is Extrawell Pharmaceutical Holdings's earnings that will influence how the balance sheet holds up in the future. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

See our latest analysis for Extrawell Pharmaceutical Holdings

Over 12 months, Extrawell Pharmaceutical Holdings made a loss at the EBIT level, and saw its revenue drop to HK$53m, which is a fall of 12%. We would much prefer see growth.

Caveat Emptor

While Extrawell Pharmaceutical Holdings's falling revenue is about as heartwarming as a wet blanket, arguably its earnings before interest and tax (EBIT) loss is even less appealing. Indeed, it lost HK$10m at the EBIT level. Having said that, the balance sheet has plenty of liquid assets for now. That should give the business time to grow its cashflow. While the stock is probably a bit risky, there may be an opportunity if the business itself improves, allowing the company to stage a recovery. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. For example, we've discovered 2 warning signs for Extrawell Pharmaceutical Holdings (1 shouldn't be ignored!) that you should be aware of before investing here.

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.